Comparing the current results to its competitors, Labcorp Holdings Inc reported Revenue increase in the 1 quarter 2026 by 5.75 % year on year. The revenue growth was below Labcorp Holdings Inc 's competitors' average revenue growth of 7.11 %, achieved in the same quarter.
Labcorp Holdings Inc Net Income in the 1 quarter 2026 grew year on year by 30.52%, faster than the Labcorp Holdings Inc 's competitors average income growth of 16.44 %
Labcorp Holdings Inc 's Comment on Competition and Industry Peers
The company faces risks associated with the competitive landscape, including consolidation and convergence among customers, competitors, and suppliers. These changes may impact insourcing, utilization, pricing, reimbursement, and supply chain access. Additional risks include failure to invest in or develop new systems, ineffective management of acquisitions, and difficulties in retaining key customers and employees during acquisition integration.
Quest Diagnostics Inc operates as a leading provider of clinical laboratory and diagnostic information services, catering to patients, healthcare professionals, hospitals, and pharmaceutical companies. The company generates revenue through a comprehensive suite of diagnostic testing services, encompassing routine lab tests, advanced molecular diagnostics, and a variety of specialized tests tailored to support clinical decision-making and patient care.
Hologic Incs business model focuses on developing and commercializing medical technologies and diagnostic products, primarily dedicated to womens healthcare. Their offerings include innovative solutions for breast and skeletal health, gynecological health, and surgical products, aiming to improve patient outcomes and enhance healthcare practices.
IQVIA Holdings Inc operates a multifaceted business model that focuses on delivering advanced analytics, technology solutions, and clinical research services tailored for the healthcare sector. By harnessing extensive data resources and industry expertise, the company aids clients in optimizing operations, enhancing drug development processes, and ultimately improving patient outcomes.
iSpecimen Inc's business model revolves around connecting researchers with the biospecimens they need for their scientific and medical studies. They serve as an intermediary platform that links healthcare organizations and biobanks to the research community, providing a streamlined process for sourcing human biosamples and associated data.
Sources:
Labcorp Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Labcorp Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
